ALGERI, MATTIA
 Distribuzione geografica
Continente #
AS - Asia 2.332
SA - Sud America 1.489
NA - Nord America 1.054
EU - Europa 397
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.361
Nazione #
BR - Brasile 1.159
US - Stati Uniti d'America 985
SG - Singapore 867
VN - Vietnam 666
CN - Cina 355
IN - India 176
AR - Argentina 133
IT - Italia 124
EC - Ecuador 89
DE - Germania 66
ID - Indonesia 61
BD - Bangladesh 41
CO - Colombia 37
HK - Hong Kong 36
MX - Messico 34
GB - Regno Unito 33
ZA - Sudafrica 27
RU - Federazione Russa 26
UA - Ucraina 26
NL - Olanda 24
PY - Paraguay 24
IQ - Iraq 22
AT - Austria 20
FI - Finlandia 20
MA - Marocco 20
PK - Pakistan 19
CA - Canada 17
CL - Cile 17
FR - Francia 14
SA - Arabia Saudita 13
PE - Perù 12
VE - Venezuela 12
KE - Kenya 11
PL - Polonia 10
TN - Tunisia 10
TR - Turchia 10
UZ - Uzbekistan 10
EG - Egitto 8
ES - Italia 8
AZ - Azerbaigian 6
IL - Israele 6
UY - Uruguay 6
CZ - Repubblica Ceca 5
DZ - Algeria 5
JO - Giordania 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
NP - Nepal 4
QA - Qatar 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
HN - Honduras 3
IE - Irlanda 3
IR - Iran 3
LB - Libano 3
TW - Taiwan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CR - Costa Rica 2
GA - Gabon 2
GE - Georgia 2
JP - Giappone 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
PA - Panama 2
RS - Serbia 2
SE - Svezia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
BW - Botswana 1
CH - Svizzera 1
CY - Cipro 1
GT - Guatemala 1
JM - Giamaica 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
NE - Niger 1
OM - Oman 1
PH - Filippine 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.361
Città #
San Jose 361
Singapore 297
Ho Chi Minh City 251
Santa Clara 170
Bengaluru 149
Hefei 149
Hanoi 146
Ashburn 135
Dallas 102
São Paulo 86
Beijing 75
Hong Kong 36
Munich 36
Rio de Janeiro 36
Guayaquil 34
Haiphong 32
Da Nang 29
Rome 28
Quito 20
Belo Horizonte 19
Thái Bình 19
Campinas 18
Porto Alegre 18
Biên Hòa 17
Brasília 17
Curitiba 17
Buenos Aires 16
Milan 16
Ribeirão Preto 16
Johannesburg 15
Hải Dương 14
Helsinki 13
Guarulhos 12
Nuremberg 12
Thái Nguyên 12
Boardman 11
Fortaleza 11
London 11
Orem 11
Salvador 11
Amsterdam 10
Asunción 10
Goiânia 10
Nairobi 10
New York 10
Tashkent 10
Baghdad 9
Bogotá 9
Bắc Ninh 9
Can Tho 9
Santo André 9
Cape Town 8
Chicago 8
Jakarta 8
Lấp Vò 8
Mexico City 8
Palermo 8
Quảng Ngãi 8
Sorocaba 8
Uberlândia 8
Corrientes 7
Duque de Caxias 7
Juiz de Fora 7
Lima 7
Los Angeles 7
Medellín 7
Ourinhos 7
Recife 7
Riyadh 7
São Bernardo do Campo 7
Tunis 7
Warsaw 7
Baku 6
Belém 6
Bento Gonçalves 6
Boydton 6
Dhaka 6
Ha Long 6
Joinville 6
Maceió 6
Ninh Bình 6
Osasco 6
Turku 6
Vallefiorita 6
Amman 5
Araraquara 5
Bauru 5
Bình Dương 5
Ciudad del Este 5
Columbus 5
Falkenstein 5
Macapá 5
Mauá 5
Montreal 5
Nha Trang 5
Nova Iguaçu 5
Santa Maria 5
Santiago 5
Suzano 5
São Luís 5
Totale 2.891
Nome #
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma 69
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL 68
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 62
Autologous gene therapy for hemoglobinopathies: From bench to patient's bedside 60
Betibeglogene autotemcel gene therapy for non–β0/β0 genotype β-thalassemia 56
Availability of HLA-allele-matched unrelated donors and registry size: Estimation from haplotype frequency in the Italian population 55
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation 53
Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor 51
Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency 49
IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ALPHA-BETA T-CELL DEPLETED HAPLO-HSCT 49
TCRab/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders 48
CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia 48
Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease and Graft Failure in Patients with Non-Malignant Disorders: Results of a Multicentre, Randomized, Open-Label Study 46
Autologous CD19‐Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis 45
A new BSA-based Threshold Predicts Optimal PBSC Collection in T-cell Depleted HLA-haploidentical Stem Cell Transplantation 45
GENERATION OF CYTOTOXIC T LYMPHOCYTES BY DONOR-SPECIFIC CSE PEPTO WT1 AND WITH CYTOTOXIC ACTIVITY TOWARDS LEUKEMIC BLASTS OF THE PATIENT FOR ADOPTIVE IMMUNOTHERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS. 45
Immune Modulation Properties of Zoledronic Acid on TcRγδ T-Lymphocytes After TcRαβ/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia 45
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome 45
Gata2 related conditions and predisposition to pediatric myelodysplastic syndromes 45
Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia 44
ABATACEPT REDUCES ACUTE GVHD INCIDENCE IN PEDIATRIC PATIENTS TRANSPLANTED FROM HLA-MISMATCHED UNRELATED DONORS 44
T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies 44
Management of pediatric patients with anti-HLA antibodies undergoing T-cell depleted haploidentical hematopoietic stem cell transplantation 44
Circulating Extracellular Vesicles Impair Mesenchymal Stromal Cell Differentiation Favoring Adipogenic Rather than Osteogenic Differentiation in Adolescents with Obesity 44
T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders 44
T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica 43
Outcome of children with acute leukemia given allogeneic HSCT either from an unrelated donor (UD-HSCT) or from an HLA-partially matched relative after αß-T cell/B-cell depletion (αßhaplo-HSCT) 43
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia 43
Resistance to neoplastic transformation of ex-vivo expanded human mesenchymal stromal cells after exposure to supramaximal physical and chemical stress 43
Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL? 43
Decellularized esophageal tubular scaffold microperforated by quantum molecular resonance technology and seeded with mesenchymal stromal cells for tissue engineering esophageal regeneration 43
FINAL RESULTS OF THE PHASE 3 STUDIES NORTHSTAR-2 AND NORTHSTAR-3 IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT): SUBGROUP ANALYSIS OF ITALIAN PATIENTS TREATED WITH BETIBEGLOGENE AUTOTEMCEL (BETI-CEL), LENTIGLOBIN FOR THALASSEMIA 42
Alpha/beta T-cell depleted Haploidentical HSCT followed by infusion of donor lymphocytes transduced with inducible caspase9 gene is safe and effective for patients with erythroid disorders 42
Comprehensive characterization of bone-marrow mesenchymal stromal cells isolated from patients affected by primary immunodeficiency 42
Cord blood transplantation for acute leukemia 42
Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (Tbdepl-Haplohsct) in Children with Non-Malignant Disorders 42
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy 41
Natural history of Ras‐associated autoimmune leukoproliferative disorder: A 20-year follow-up of a NRAS-mutated patient excluding a malignant progression 41
T- and B-Cell Neogenesis Recovers Efficiently in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Followed By Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 cells) 41
LONG-TERM DATA ON IMMUNE MONITORING OF CHILDREN GIVEN TCRαβ/CD19 CELL DEPLETED HLA-HAPLOIDENTICAL STEM TRANSPLANTATION (HAPLO-HSCT) 41
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors 41
TCRαβ +/CD19 + - Depleted HLA-Haploidentical Hematopoietic Stem Cell Traansplantation in Pediatric Patient with Fanconi Anemia 41
BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS 41
P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL 41
Biological and functional characterization of bone marrow-derived mesenchymal stromal cells isolated from pediatric patients affected by acute myeloid leukemia 41
TCRαβ/CD19 cell–depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis 40
Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ haplo-HSCT) Contributing to Accelerate Immune Recovery 40
Pre-Transplant Levels of Multiparametric Flow-Cytometry Measurable Residual Disease (MFC-MRD) Predict Outcomes in Children with Acute Myeloid Leukemia Given Allogeneic Hematopoietic Stem Cell Transplantation 40
Use of emapalumab in the peri-transplant period to prevent graft failure in patients at risk 40
Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia 40
Use of Ruxolitinib in Pediatric Patients with Steroid-Refractory Graft-versus-host Disease (GVHD) 40
NIRMATRELVIR/RITONAVIR AND TIXAGEVIMAB/CILGAVIMAB AS SARS-COV-2 TREATMENT IN PEDIATRIC AND YOUNG ADULT PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OR CD19-DIRECTED CAR T-CELL TREATMENT 39
Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders 39
Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children 39
Outcome of children with ALL in second complete remission transplanted from an unrelated donor: a retrospective analysis 39
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy 39
Outcome of Children with Acute Leukemia Given Allogeneic HSCT Either from an Unrelated Donor or from an HLA-Partially Matched Relative after αβ-T Cell/B-Cell Depletion: A Multicenter, Retrospective, Comparative Analysis of the AIEOP Network 39
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation 39
A new promising, third-generation (3RD) CAR-CD30 T cells therapy for CD30+lymphoma patients 39
Treosulfan Exposure in Pediatric Hematopoietic Stem Cell Transplantation is Associated with Early Toxicity but not with event-free Survival 38
Improved T- and B-Cell Neogenesis in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Combined with the Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (Rivo-cel) 38
SUCCESS OF PERSONALIZED RUXOLITINIB TREATMENT BASED ON THERAPEUTIC DRUG MONITORING IN PEDIATRIC PATIENTS WITH PRIMARY AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ALLOWING BRIDGING TO HSCT 38
Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT) in Children with Myelodysplastic Syndromes 38
Decolonization of multi-drug resistant bacteria by fecal microbiota transplantation in five pediatric patients before allogeneic hematopoietic stem cell transplantation: Gut microbiota profiling, infectious and clinical outcomes 38
Engineered mucoperiosteal scaffold for cleft palate regeneration towards the non-immunogenic transplantation 38
Unmanipulated donor lymphocyte infusion (dli) after ab-t and b-cell depleted haploidentical stem cell transplantation 38
Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease 38
Genome editing for sickle cell disease: still time to correct? 38
HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties 37
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia 37
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL) 37
Unrelated donor vs HLA-haploidentical a/b T-cell– and B-cell–depleted HSCT in children with acute leukemia 37
Brentuximab in Children, Adolescent and Young Adults with Relapsed/Refractory Anaplastic Large Cell Lymphoma 37
Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders 37
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia 37
Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT) 37
Allogeneic CD19-CAR T cells: a promising treatment for pediatric patients with highly refractory BCP-ALL relapsing after allogeneic hematopoietic stem cells transplant (allo-HSCT) 36
Phenotypic and functional characterization of mesenchymal stromal cells isolated from pediatric patients with severe idiopathic nephrotic syndrome 36
Lentiglobin Gene Therapy Treatment of Two Patients with Transfusion-dependent ß-thalassemia 36
Lymphocyte Collection for Generation of CAR T-cells in Pediatric Patients: A Single Center Experience 36
THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS 36
Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders 36
Successful muscle regeneration by a homologous microperforated scaffold seeded with autologous mesenchymal stromal cells in a porcine esophageal substitution model 35
Outcome of Children with Different Non-Malignant Disorders Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT) 35
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia 35
Intramedullary spinal cord cavernous malformations presenting with unexplained chest pain: Case report and review of the literature 35
Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major 35
The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children 34
Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study 34
Outcomes of children with primary immunodeficiencies receiving alpha/beta T-cell depleted HLA-haplo-HSCT followed by infusion of lymphocytes transduced with the inducible caspase 9 (iC9) suicide gene 34
Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study 34
Dissecting the mechanisms of bone loss in Gorham-Stout disease 34
Outcome of Children with Wiskott-Aldrich Syndrome (WAS) Given TCR Alpha-Beta/CD19 Depleted Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Haploidentical Relative 34
CD19 REDIRECTED CAR NK CELLS ARE EQUALLY EFFECTIVE BUT LESS TOXIC THAN CAR T CELLS IN ACUTE LYMPHOBLASTIC LEUKEMIA 34
Remestemcel-L for the treatment of graft versus host disease 34
Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes 34
Monitoring of T-cell responses to viral-coded antigens in pediatric patients receiving TCRαβ-depleted haplo-HSCT followed by BPX-501 cell administration 34
Mesenchymal stromal cells and chronic inflammatory bowel disease 34
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Cerebral Adrenoleukodystrophy: Outcomes by Donor Cell Source And Match, Conditioning Regimen, And Stage of Cerebral Disease 34
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia 33
Totale 4.107
Categoria #
all - tutte 28.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.675


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 0 12 0
2024/20251.185 4 0 3 402 66 165 60 29 95 70 59 232
2025/20264.374 75 395 813 1.601 319 59 275 217 428 192 0 0
Totale 5.571